• Developed a new oral liquid formulation of NUZ-001 for ALS treatment
• Designed to support patients with swallowing difficulties, ensuring broader access
• Part of Neurizon's patient-centric innovation strategy to enhance treatment experience

Neurizon Therapeutics Limited, a clinical-stage biotech company dedicated to advancing treatments for neurodegenerative diseases, has announced the development of a new oral liquid formulation of NUZ-001, its lead investigational therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS). This advancement represents a significant step toward improving accessibility, ease of administration, and overall treatment experience for patients living with ALS. The newly developed oral liquid formulation reflects Neurizon's commitment to innovation that addresses the real-world challenges faced by people affected by ALS. For many patients, especially those experiencing bulbar onset or progressive difficulty swallowing, tablet-based medication can become increasingly hard to manage as the disease advances. The oral liquid formulation provides an important alternative, ensuring more patients can continue to benefit from NUZ-001 throughout their journey. Developed in direct response to feedback from patients and carers, this formulation reflects Neurizon's belief that the patient voice should guide both trial design and treatment delivery. The key advantages of the liquid formulation include improved ease of swallowing for patients with dysphagia or speech impairment, flexible dosing across a range of patient weights and tolerances, enteral (feeding tube) administration, and simplified administration for caregivers and clinical teams. The development of the liquid formulation also marks the launch of a life cycle management (LCM) strategy for NUZ-001, transforming the drug from a single-asset product into a long-term, scalable treatment platform to enhance both patient value and commercial success.

Neurizon remains committed to advancing accessible, patient-informed therapeutic solutions that reflect the lived experience of those affected by ALS. The liquid formulation is currently being integrated into Neurizon's ongoing clinical development program for NUZ-001 and will be evaluated for bioequivalence and patient acceptability alongside the standard tablet form, with a human bioequivalence study scheduled to commence in H1 CY 2026.